Consumer demand for GLP-1 drugs like Ozempic and Wegovy has drawn a flood of new entrants. Yaccarino will have to find a way to differentiate eMed, analysts said.
Consumer demand for GLP-1 drugs like Ozempic and Wegovy has drawn a flood of new entrants. Yaccarino will have to find a way to differentiate eMed, analysts said.